Anti-VEGF therapy for renal cell carcinoma

Clinical Advances in Hematology and Oncology

Volumn 5, Issue 7, 2007, Pages 530-531

  Escudier, Bernard ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; INTERFERON; INTERLEUKIN 2; PLACEBO; SUNITINIB; TEMSIROLIMUS; TORISEL; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESEARCH; DRUG TREATMENT FAILURE; FATIGUE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MONOTHERAPY; PROGNOSIS; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CLINICAL TRIALS; HUMANS; INTERFERON ALFA-2A; KIDNEY NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34848865338     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Escudier B, Koralewski P, Pluzanksa A, et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-a2a vs placebo/interferon-a2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol. 2007;25(18S pt 1): Abstract 3.
2. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007 Jun 18; [Epub ahead of print].
3. Escudier B. Advanced renal cell carcinoma: current and emerging management strategies. Drugs. 2007;67:1257-1264.
4. Rini BI, Jaeger E, Weinberg V, et al. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int. 2006;98:756-762.
5. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL; Cancer and Leukemia Group B. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor anti-body (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res. 2004;10: 2584-2586.
6. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.